DRD2
ENSG00000149295
Target class
GPCR
Chromosome
11
Approved drugs
73
Clinical candidates (approved and in development)
98
- Approved drugs
- 73
- Clinical candidates (approved and in development)
- 98
- Chemical probe available
- Yes
- Other names
- D2R
- Target name
- DRD2
- Gene name
- Dopamine receptor D2
- Gene symbol
- DRD2
- Protein name
- D(2) dopamine receptor (Dopamine D2 receptor)
- Gene biotype
- Protein coding
- Gene family
- Dopamine receptors|MicroRNA protein coding host genes
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 14
- Highest tissue expression
- 81.44
- Tissue specificity (Gini)
- 0.867
- Tissue specificity (tau)
- 0.956
- KEGG gene identifiers
- hsa:1813
- Reactome pathways
- R-HSA-390651
- Protein interaction confidence
- 0.862821
- Protein interaction partners
- 67
- End position
- 113476402
- Start position
- 113409605
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Golgi apparatus membrane
- Multi-pass membrane protein .
- PubMed 21645528
- PubMed 26535572
- Tissue specificity (tau)
- 0.955664
- Expression inequality (Gini)
- 0.867413
Expression in transcripts per million
- Pituitary
- 81.44
- Brain - Nucleus accumbens (basal ganglia)
- 51.91
- Brain - Putamen (basal ganglia)
- 45.74
- Brain - Caudate (basal ganglia)
- 40.7
- Minor Salivary Gland
- 11.45
Expression in transcripts per million
- Pituitary81.44
- Brain - Nucleus accumbens (basal ganglia)51.91
- Brain - Putamen (basal ganglia)45.74
- Brain - Caudate (basal ganglia)40.7
- Minor Salivary Gland11.45
- Brain - Substantia nigra8.66
- Brain - Hypothalamus6.5
- Nerve - Tibial4.03
- Cervix - Endocervix1.85
- Testis1.75
- Brain - Amygdala1.57
- Brain - Cortex1.23
- Brain - Frontal Cortex (BA9)1.04
- Brain - Cerebellum1.03
- Brain - Cerebellar Hemisphere0.93
- Brain - Hippocampus0.91
- Prostate0.9
- Brain - Anterior cingulate cortex (BA24)0.87
- Fallopian Tube0.85
- Skin - Sun Exposed (Lower leg)0.82
- Breast - Mammary Tissue0.75
- Uterus0.66
- Brain - Spinal cord (cervical c-1)0.65
- Skin - Not Sun Exposed (Suprapubic)0.63
- Artery - Aorta0.59
And 29 more, listed on the interactive page.
- GO:0007195
- GO:0032467
- GO:0034776
- GO:0042417
- GO:0050482
- GO:0050709
- GO:0051584
- GO:0060158
- GO:1900168
- GO:0000139
- GO:0005886
- GO:0005929
- GO:0060170
- GO:0097648
- GO:0097730
- GO:0001591
- GO:0001965
- GO:0005515
- GO:0032795
- GO:0042802
decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264fainting
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: fainting
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264heart failure
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: heart failure
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264vomiting
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: vomiting
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264stereotypy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: stereotypy
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264confusion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: confusion
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pituitary hormone secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pituitary hormone secretion
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264drowsiness
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drowsiness
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased locomotor activity
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood pressure
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased urinary sodium excretion
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264catalepsy
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: catalepsy
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased Locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased Locomotor activity
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased gastrointestinal transit
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264hallucinations
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hallucinations
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: orthostatic hypotension
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264fibrotic valvular heart disease
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: fibrotic valvular heart disease
- renal
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
emesis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: emesis
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038drowsiness
- Inhibition/Decrease/Downregulation: general
- Activation/Increase/Upregulation: general
Studies
- preclinical: drowsiness
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038confusion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: confusion
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038syncope
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: syncope
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hDRD2s, is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD2s assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceincreased sodium excretion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased sodium excretion
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: orthostatic hypotension
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038hallucinations
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hallucinations
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038decreased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased heart rate
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038increased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased gastrointestinal motility
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038decreased pituitary hormone secretions
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased pituitary hormone secretions
- cardiovascular system
- central nervous system
- endocrine
PubMed 23197038
Related records
Trials (2,791)
- "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
- 12- Week Open Label Treatment of Refractory Bipolar Depression
- 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
Drugs (122)
- Acetophenazine Dopamine D2 receptor antagonist
- Acetophenazine maleate Dopamine D2 receptor antagonist
- Adoprazine Dopamine D2 receptor antagonist
- Alizapride Dopamine D2 receptor antagonist
- Amineptine Dopamine D1 and D2 receptor antagonist
- Amisulpride Dopamine receptors; D2 & D3 antagonist
- Amoxapine Dopamine receptor antagonist
- Aplindore Dopamine D2 receptor partial agonist
- Aplindore fumarate Dopamine D2 receptor partial agonist
- Apomorphine D2-like dopamine receptor agonist
- Apomorphine hydrochloride D2-like dopamine receptor agonist
- Aripiprazole Dopamine D2 receptor partial agonist
- Aripiprazole lauroxil Dopamine D2 receptor partial agonist
- Asenapine Dopamine D2 receptor antagonist
- Asenapine maleate Dopamine D2 receptor antagonist
- Benperidol Dopamine D2 receptor antagonist
- Benzquinamide Dopamine D2 receptor modulator
- Benzquinamide hydrochloride Dopamine D2 receptor modulator
- Bifeprunox Dopamine D2 receptor partial agonist
- Blonanserin Dopamine D2 receptor antagonist